Passage Bio
PASG
39 hedge funds and large institutions have $33M invested in Passage Bio in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 7 closing their positions.
240% more call options, than puts
Call options by funds: $17K | Put options by funds: $5K
157% more capital invested
Capital invested by funds: $12.8M → $33M (+$20.2M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
0.11% less ownership
Funds ownership: 2.93% → 2.82% (-0.11%)
5% less funds holding
Funds holding: 41 → 39 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$90.5K |
| 2 |
RWM
Ritholtz Wealth Management
New York
|
+$9.28K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.39K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$5.66K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$4.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$358K |
| 2 |
SC
Shay Capital
New York
|
-$51.8K |
| 3 |
Millennium Management
New York
|
-$45.8K |
| 4 |
BlackRock
New York
|
-$45.2K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$32.9K |
PASG Hedge Fund Activity: Q2 2025 in Review
39 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q2 2025, worth a combined $33M — up 157% from $12.8M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PASG and 5 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $90.5K. The largest seller was OrbiMed, cutting an estimated $358K.
- 39 institutional investors held Passage Bio (PASG) as of Q2 2025, down from 41 in Q1 2025.
- Funds reported $33M of Passage Bio stock for Q2 2025, up 157% quarter-over-quarter.
- 5 funds opened new Passage Bio positions in Q2 2025 and 7 closed out, a net change of -2 holders.
- The largest Passage Bio buyer in Q2 2025 was Citadel Advisors, an estimated $90.5K added.
- The largest Passage Bio seller in Q2 2025 was OrbiMed, an estimated $358K sold.
Based on aggregated 13F filings for Q2 2025.